3.44

2.69% 0.09

Relmada Therapeutics Inc (RLMD)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione Frazionamento azionario

Precedente Chiudi:

$3.35

Aprire:

$3.38

Volume 24 ore:

1.61M

Relative Volume:

0.92

Capitalizzazione di mercato:

$366.94M

Reddito:

Utile/perdita netta:

$-58.88M

Rapporto P/E:

-3.0924

EPS:

-1.1124

Flusso di cassa netto:

$-42.79M

1 W Prestazione:

+4.56%

1M Prestazione:

-7.77%

6M Prestazione:

-53.32%

1 anno Prestazione:

+40.41%

Intervallo 1D:

$3.29

$3.485

Intervallo di 1 settimana:

$3.175

$3.485

Portata 52W:

$2.15

$8.00

Relmada Therapeutics Inc Stock (RLMD) Company Profile

Nome

Relmada Therapeutics Inc

Settore

Healthcare (1052)

Industria

Biotechnology (595)

Telefono

646 876 3459

Indirizzo

2222 PONCE DE LEON BLVD. 3RD FLOOR, CORAL GABLES, NY

Dipendente

Cinguettio

@relmada

Prossima data di guadagno

2026-11-12

Ultimi documenti SEC

RLMD's Discussions on Twitter

Compare RLMD vs VRTX, MRNA, REGN, ARGX, ONC

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
RLMD Relmada Therapeutics Inc	3.44	366.94M	0	-58.88M	-42.79M	-1.1124
VRTX Vertex Pharmaceuticals Inc	540.00	136.87B	12.34B	4.34B	3.71B	16.87
MRNA Moderna Inc	222.76	88.93B	2.23B	-3.19B	-1.60B	-8.1462
REGN Regeneron Pharmaceuticals Inc	818.77	84.30B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	897.85	56.46B	4.16B	1.29B	734.26M	19.58
ONC Beone Medicines Ltd Adr	371.56	42.03B	5.76B	514.49M	1.10B	4.4813

Relmada Therapeutics Inc Stock (RLMD) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-06-18	Iniziato	H.C. Wainwright	Buy
2026-03-24	Iniziato	Piper Sandler	Overweight
2026-01-23	Ripresa	Leerink Partners	Outperform
2025-12-22	Iniziato	Jefferies	Buy
2025-11-19	Aggiornamento	Mizuho	Neutral → Outperform
2024-12-05	Downgrade	Mizuho	Outperform → Neutral
2024-09-17	Aggiornamento	Jefferies	Hold → Buy
2024-06-05	Downgrade	Goldman	Neutral → Sell
2022-10-14	Downgrade	Goldman	Buy → Neutral
2022-10-14	Downgrade	Guggenheim	Buy → Neutral
2022-10-14	Downgrade	Truist	Buy → Hold
2022-10-13	Downgrade	Oppenheimer	Outperform → Perform
2021-11-18	Iniziato	Mizuho	Buy
2021-05-20	Ripresa	Goldman	Buy
2020-10-28	Downgrade	Goldman	Buy → Neutral
2020-07-14	Iniziato	Oppenheimer	Outperform
2020-05-04	Iniziato	SunTrust	Buy
2020-04-21	Iniziato	Goldman	Buy
2020-01-27	Iniziato	Jefferies	Buy
2020-01-10	Iniziato	SVB Leerink	Outperform
2019-12-16	Iniziato	Guggenheim	Buy

Mostra tutto

Relmada Therapeutics Inc Borsa (RLMD) Ultime notizie

Sep 29, 2026

Relmada Therapeutics Inc Statistics – HAN:4E2 - TradingView

Sep 29, 2026

Sep 14, 2026

Relmada: 'Hold' Based On Needed NVD-01 Manufacturing Push For IND YE2026 And Sepranolone Advancement - Seeking Alpha

Sep 14, 2026

Top insider buys and sells disclosed on Friday - Investing.com

Sep 14, 2026

Top insider buys and sells disclosed on Friday By Investing.com - Investing.com UK

Sep 14, 2026

Sep 13, 2026

Relmada CEO Sergio Traversa buys 200,000 shares for $828,000 By Investing.com - Investing.com Nigeria

Sep 11, 2026

Relmada CEO Sergio Traversa buys 200,000 shares for $828,000 By Investing.com - Investing.com South Africa

Sep 11, 2026

12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga

Sep 11, 2026

Relmada CEO Sergio Traversa buys 200,000 shares for $828,000 - Investing.com India

Sep 11, 2026

Relmada Therapeutics CFO Maged Shenouda buys $843,990 in shares - Investing.com

Sep 11, 2026

Relmada Therapeutics CFO Maged Shenouda buys $843,990 in shares By Investing.com - Investing.com India

Sep 11, 2026

Relmada CEO Sergio Traversa buys 200,000 shares for $828,000 By Investing.com - Investing.com Canada

Sep 11, 2026

Relmada Therapeutics CFO Maged Shenouda buys $843,990 in shares By Investing.com - Investing.com UK

Sep 11, 2026

Relmada CEO Sergio Traversa buys 200,000 shares for $828,000 By Investing.com - Investing.com UK

Sep 11, 2026

Relmada Therapeutics CFO Maged Shenouda buys $843,990 in shares - investing.com

Sep 11, 2026

Relmada Therapeutics Insiders Purchased Shares Worth Over $1.6M - TradingView

Sep 11, 2026

Relmada (NASDAQ: RLMD) CEO buys stock in two open-market trades - Stock Titan

Sep 11, 2026

Relmada Therapeutics (RLMD) CFO buys 200,000 shares in open market - Stock Titan

Sep 11, 2026

Relmada Therapeutics CEO Sergio Traversa Acquires 200,000 Shares in Two-Day Open Market Transactions - Kalkine Media

Sep 11, 2026

Relmada Therapeutics CEO Sergio Traversa Acquires 200,000 Shares at $4.10-$4.18 (NASDAQ: RLMD) - Kalkine Media

Sep 11, 2026

Relmada CEO Sergio Traversa buys 200,000 shares for $828,000 - Investing.com

Sep 11, 2026

Sep 09, 2026

Relmada Therapeutics (NASDAQ: RLMD) Announces Departure of CMO Dr. Raj S. Pruthi Effective September 3, 2026 - Kalkine Media

Sep 09, 2026

Sep 08, 2026

Relmada Therapeutics Announces Urology Chief Medical Officer Exit - TipRanks

Sep 08, 2026

Sep 02, 2026

Relmada’s NDV-01 Bladder Cancer Trial Moves Into Phase 3: What Investors Should Watch - TipRanks

Sep 02, 2026

Sep 01, 2026

Relmada Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference - The Manila Times

Sep 01, 2026

Senior managers will hold one-on-one meetings in Boston at a Wells Fargo healthcare conference Sept. 8-10. - stocktitan.net

Sep 01, 2026

Aug 31, 2026

After Plunging 18.5% in 4 Weeks, Here's Why the Trend Might Reverse for Relmada Therapeutics (RLMD) - Yahoo Finance

Aug 31, 2026

Aug 29, 2026

Relmada Therapeutics (RLMD) Slides 4.2% to $4.33 as Clinical-Stage Pressures WeighAdvance Decline Line - vinanet.vn

Aug 29, 2026

Relmada Therapeutics (RLMD) Slides 4.2% to $4.33 as Clinical-Stage Pressures WeighMcClellan Oscillator - dars.gov.et

Aug 29, 2026

Aug 28, 2026